Douglawi A. Masterson T.A.

Updates on the epidemiology and risk factors for penile cancer.

Transl Androl Urol. 6: 785-790Hernandez B.Y. Barnholtz-Sloan J. German R.R. et al.

Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003.

Cancer. 113: 2883-2891Pow-Sang M.R. Ferreira U. Pow-Sang J.M. et al.

Epidemiology and natural history of penile cancer.

Urology. 76: S2-S6Leto M. Santos Junior G.F. Porro A.M. et al.

Human papillomavirus infection: etiopathogenesis, molecular biology and clinical manifestations.

An Bras Dermatol. 86: 306-317Spiess P.E. Dhillon J. Baumgarten A.S. et al.

Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies.

CA Cancer J Clin. 66: 481-495Stratton K.L. Culkin D.J.

A contemporary review of HPV and penile cancer.

Oncology (Williston Park). 30: 245-249Olesen T.B. Sand F.L. Rasmussen C.L. et al.

Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis.

Lancet Oncol. 20: 145-158Weaver B.A. Feng Q. Holmes K.K. et al.

Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men.

J Infect Dis. 189: 677-685Chipollini J. Chaing S. Azizi M. et al.

Advances in understanding of penile carcinogenesis: the search for actionable targets.

Int J Mol Sci. 18Agarwal G. Gupta S. Spiess P.E.

Novel targeted therapies for the treatment of penile cancer.

Expert Opin Drug Discov. 9: 959-968Scheffner M. Werness B.A. Huibregtse J.M. et al.

The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

Cell. 63: 1129-1136Ferreux E. Lont A.P. Horenblas S. et al.

Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus.

J Pathol. 201: 109-118Lopes A. Bezerra A.L. Pinto C.A. et al.

p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.

J Urol. 168: 81-86Djajadiningrat R.S. Jordanova E.S. Kroon B.K. et al.

Human papillomavirus prevalence in invasive penile cancer and association with clinical outcome.

J Urol. 193: 526-531Lont A.P. Kroon B.K. Horenblas S. et al.

Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival.

Int J Cancer. 119: 1078-1081Bezerra A.L. Lopes A. Santiago G.H. et al.

Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.

Cancer. 91: 2315-2321Fonseca A.G. Soares F.A. Burbano R.R. et al.

Human papilloma virus: prevalence, distribution and predictive value to lymphatic metastasis in penile carcinoma.

Int Braz J Urol. 39: 542-550Steinestel J. Al Ghazal A. Arndt A. et al.

The role of histologic subtype, p16(INK4a) expression, and presence of human papillomavirus DNA in penile squamous cell carcinoma.

BMC Cancer. 15: 220Trimble C.L. Morrow M.P. Kraynyak K.A. et al.

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Lancet. 386: 2078-2088Stevanovic S. Draper L.M. Langhan M.M. et al.

Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.

J Clin Oncol. 33: 1543-1550Aydin A.M. Hall M. Bunch B.L. et al.

Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients.

Int Immunopharmacol. 94: 107481Stankiewicz E. Prowse D.M. Ng M. et al.

Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas.

PloS one. 6: e17517Chaux A. Munari E. Katz B. et al.

The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases.

Hum Pathol. 44: 2690-2695McDaniel A.S. Hovelson D.H. Cani A.K. et al.

Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy.

Cancer Res. 75: 5219-5227Di Lorenzo G. Perdona S. Buonerba C. et al.

Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study.

J Transl Med. 11: 161Necchi A. Lo Vullo S. Perrone F. et al.

First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.

BJU Int. 121: 348-356Thomas A. Reetz S. Stenzel P. et al.

Assessment of PI3K/mTOR/AKT pathway elements to serve as biomarkers and therapeutic targets in penile cancer.

Cancers (Basel). 13: 2323Thomas A. Slade K.S. Blaheta R.A. et al.

Value of c-MET and associated signaling elements for predicting outcomes and targeted therapy in penile cancer.

Cancers (Basel). 14: 1683Chahoud J. Gleber-Netto F.O. McCormick B.Z. et al.

Whole-exome sequencing in penile squamous cell carcinoma uncovers novel prognostic categorization and drug targets similar to head and neck squamous cell carcinoma.

Clin Cancer Res. 27: 2560-2570Ottenhof S.R. Djajadiningrat R.S. Thygesen H.H. et al.

The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma.

Front Immunol. 9: 1253Vassallo J. Rodrigues A.F. Campos A.H. et al.

Pathologic and imunohistochemical characterization of tumoral inflammatory cell infiltrate in invasive penile squamous cell carcinomas: Fox-P3 expression is an independent predictor of recurrence.

Tumour Biol. 36: 2509-2516Ahmed M.E. Falasiri S. Hajiran A. et al.

The immune microenvironment in penile cancer and rationale for immunotherapy.

J Clin Med. 9: 3334Azizi M. Aydin A.M. Hajiran A. et al.

Systematic review and meta-analysis-is there a benefit in using neoadjuvant systemic chemotherapy for locally advanced penile squamous cell carcinoma?.

J Urol. 203: 1147-1155Udager A.M. Liu T.Y. Skala S.L. et al.

Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.

Ann Oncol. 27: 1706-1712Hahn A.W. Chahoud J. Campbell M.T. et al.

Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial.

Invest New Drugs. 39: 1405-1410Chahoud J. Skelton WPt Spiess P.E. et al.

Case report: two cases of chemotherapy refractory metastatic penile squamous cell carcinoma with extreme durable response to pembrolizumab.

Front Oncol. 10: 615298Marabelle A. Fakih M. Lopez J. et al.

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

Lancet Oncol. 21: 1353-1365